Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delineation of <i>MGMT</i> Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

1 May 2015

Abstract excerpt

BACKGROUND: Sensitizing effects of poly-ADP-ribose polymerase inhibitors have been studied in several preclinical models, but a clear understanding of predictive biomarkers is lacking. In this study, in vivo efficacy of veliparib combined with temozolomide (TMZ) was evaluated in a large panel of glioblastoma multiforme (GBM) patient-derived xenografts (PDX) and potential biomarkers were analyzed. METHODS: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26615020
DOI: 10.1093/jnci/djv369

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delineation of <i>MGMT</i> Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaPMID 26615020Read ↗

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular HeterogeneitySemantic proximity Read ↗

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision RepairSemantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Semantic proximity Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of MedulloblastomaSemantic proximity Read ↗

Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma TherapySemantic proximity Read ↗

MGMT inhibition regulates radioresponse in GBM, GSC, and melanomaSemantic proximity Read ↗

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.